High-value implants and prostheses inventory: ownership, consignment and traceability

High-value implants are exactly the category where inventory misstatement risk is largest per unit and where control failures (recognizing consignment stock as owned, or losing patient-level traceability) create both financial reporting errors and serious patient-safety/recall response risk, making this a priority area for both auditors and clinical governance.

For each implant or prosthesis supplier arrangement, does the hospital or the supplier bear the risk of loss, obsolescence and price change before a unit is used in surgery? Does the hospital have real discretion over which brand or size to use, or is usage effectively dictated by the surgeon while the supplier retains full risk until implantation? Is unit-level cost and patient traceability maintained well enough to support a recall response and to pursue warranty or defect claims against suppliers?

1) For each implant supplier arrangement, review the contractual terms to determine who bears the risk of loss, obsolescence and price changes before a specific unit is used (supplier under consignment, hospital if purchased outright). 2) Recognize as inventory only implant stock over which the hospital has obtained control (legal title or the substantive risks and rewards of ownership); exclude supplier-owned consignment stock from the statement of financial position entirely. 3) At the point a consigned unit is used in a procedure, simultaneously recognize the cost of sales and the corresponding payable to the supplier (control and the obligation to pay arise together at that moment). 4) Maintain unit-level, patient-linked traceability (specific identification, not weighted average) for high-value implants given the need to trace specific units for recalls and warranty/defect claims. 5) Reconcile physical implant counts (both owned and consignment) to accounting and clinical records regularly given the high value and small volume of these items. 6) Monitor for obsolescence risk from sizing mismatches, biologic component expiry, and model/technology changes on owned inventory.

Measure recognized implant inventory at the lower of cost and net realizable value, applying specific identification (rather than weighted average) given the high unit value and patient-specific selection, so each unit's cost and status can be individually tracked; monitor for obsolescence risk from sizing mismatches, expiry (for biologic components) and technology/model changes, writing down to NRV where recovery is doubtful; measure the payable recognized on consignment usage at the agreed unit price under the supplier arrangement.

Disclose the accounting policy for consignment implant stock; disclose the carrying amount of implant/prosthesis inventory recognized on-balance-sheet; disclose the extent of off-balance-sheet consignment stock held on the hospital's premises (a quantitative or narrative disclosure of the magnitude); disclose the inventory costing method used for high-value implants (specific identification) and any impairment/obsolescence write-downs recognized.

• Recognizing all physical implant stock on the hospital premises as owned inventory regardless of the underlying consignment terms, overstating both inventory and payables
• using a weighted-average costing approach that obscures unit-level traceability needed for recalls, undermining patient-safety response capability
• failing to reconcile physical implant counts to accounting records given the high value and small volume of these items, increasing undetected loss/theft risk
• not simultaneously recognizing the payable when a consigned unit is used, understating liabilities at that moment.